Literature DB >> 33306984

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.

Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo, Ameya Champhekar, Egmidio Medina, Davis Y Torrejon, Daniel Sanghoon Shin, Phuong Tran, Yeon Joo Kim, Cristina Puig-Saus, Katie Campbell, Agustin Vega-Crespo, Michael Quist, Christophe Martignier, Jason J Luke, Jedd D Wolchok, Douglas B Johnson, Bartosz Chmielowski, F Stephen Hodi, Shailender Bhatia, William Sharfman, Walter J Urba, Craig L Slingluff, Adi Diab, John B A G Haanen, Salvador Martin Algarra, Drew M Pardoll, Valsamo Anagnostou, Suzanne L Topalian, Victor E Velculescu, Daniel E Speiser, Anusha Kalbasi, Antoni Ribas.   

Abstract

Entities:  

Year:  2020        PMID： 33306984      PMCID： PMC7885306          DOI： 10.1016/j.ccell.2020.11.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


× No keyword cloud information.
  9 in total

Review 1.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

2.  IFNγ Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity.

Authors:  Darya Alizadeh; Robyn A Wong; Sharareh Gholamin; Madeleine Maker; Maryam Aftabizadeh; Xin Yang; Joseph R Pecoraro; John D Jeppson; Dongrui Wang; Brenda Aguilar; Renate Starr; Claire B Larmonier; Nicolas Larmonier; Min-Hsuan Chen; Xiwei Wu; Antoni Ribas; Behnam Badie; Stephen J Forman; Christine E Brown
Journal:  Cancer Discov       Date:  2021-04-09       Impact factor: 39.397

3.  Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.

Authors:  Cara Haymaker; Daniel H Johnson; Ravi Murthy; Salah-Eddine Bentebibel; Marc I Uemura; Courtney W Hudgens; Houssein Safa; Marihella James; Robert H I Andtbacka; Douglas B Johnson; Montaser Shaheen; Michael A Davies; Shah Rahimian; Srinivas K Chunduru; Denái R Milton; Michael T Tetzlaff; Willem W Overwijk; Patrick Hwu; Nashat Gabrail; Sudhir Agrawal; Gary Doolittle; Igor Puzanov; Joseph Markowitz; Chantale Bernatchez; Adi Diab
Journal:  Cancer Discov       Date:  2021-03-11       Impact factor: 39.397

4.  YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy.

Authors:  Jian Hu; Dongxu Qiu; Anze Yu; Jiao Hu; Hao Deng; Huihuang Li; Zhenglin Yi; Jinbo Chen; Xiongbing Zu
Journal:  Front Oncol       Date:  2021-05-06       Impact factor: 6.244

5.  An Immune-Related Gene Pair Index Predicts Clinical Response and Survival Outcome of Immune Checkpoint Inhibitors in Melanoma.

Authors:  Junya Yan; Xiaowen Wu; Jiayi Yu; Yan Kong; Shundong Cang
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

Review 6.  Molecular imaging to support cancer immunotherapy.

Authors:  Pim P van de Donk; Sjoukje F Oosting; Daan G Knapen; Anthonie J van der Wekken; Adrienne H Brouwers; Marjolijn N Lub-de Hooge; Derk-Jan A de Groot; Elisabeth Ge de Vries
Journal:  J Immunother Cancer       Date:  2022-08       Impact factor: 12.469

7.  Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study.

Authors:  Irene M Shui; Xiao Qiao Liu; Qing Zhao; Seung Tae Kim; Yuan Sun; Jennifer H Yearley; Tasmiah Choudhury; Andrea L Webber; Clemens Krepler; Razvan Cristescu; Jeeyun Lee
Journal:  J Immunother Cancer       Date:  2022-07       Impact factor: 12.469

Review 8.  Immunity beyond cancer cells: perspective from tumor tissue.

Authors:  Shengyu Gao; Ting-Wei Hsu; Ming O Li
Journal:  Trends Cancer       Date:  2021-07-22

9.  Transcriptomic signatures of tumors undergoing T cell attack.

Authors:  Aishwarya Gokuldass; Aimilia Schina; Martin Lauss; Katja Harbst; Christopher Aled Chamberlain; Arianna Draghi; Marie Christine Wulff Westergaard; Morten Nielsen; Krisztian Papp; Zsofia Sztupinszki; Istvan Csabai; Inge Marie Svane; Zoltan Szallasi; Göran Jönsson; Marco Donia
Journal:  Cancer Immunol Immunother       Date:  2021-07-17       Impact factor: 6.968
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.